protocolSection identificationModule nctId: NCT06319742, orgStudyIdInfo id: NSISTRCR_2201, briefTitle: Extracellular Vesicle Surface Markers In Acute Cerebrovascular Syndromes., acronym: ElViS-ACS, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-11-18, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-01-31, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Ospedale Civico, Lugano, class: OTHER_GOV, descriptionModule briefSummary: Clinical implication of eventual blood biomarkers for stroke diagnosis and prognosis would be limited, mainly because clinical evaluation and scales (providing stroke severity) or neuroimaging (providing accurate size of the lesion) are more reliable predictors for clinical outcome prediction. In clinical practice, it would be more useful to find a biomarker, which can help to orientate the physician in conditions in which the clinical picture and imaging provide a limited support.Transient Ischemic Attacks (TIAs) represent a classical example for which a biomarker would be of interest to confirm and distinguish a brain ischemic process from a stroke mimic. Diagnostic biomarkers of TIA have been investigated, but none of the potential candidates reached enough accuracy for TIA diagnosis. Our group has found that Extracellular Vesicles (EVs) could be useful as biomarkers for detecting brain ischemia in patients with TIA because the EV-surface antigen profile appears to be different in patients with transient symptoms, adjudicated to be very likely caused by brain ischemia, compared to patients whose symptoms were less likely to due to brain ischemia. Our study has raised interest in the scientific community recognizing the promising role of of blood-derived EVs analysis in expanding the possibilities to correctly diagnose and classify TIA and stroke events, discriminate them from TIA or stroke mimics, with important future implications in management and therapy of the patients with acute ischemic cerebrovascular syndrome. the validity of our approach needs to be tested in a larger, prospective, multicenter study., conditionsModule conditions: Stroke, TIA, Stroke-mimics, Stroke Biomarkers, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Extracellular vescicles (EV) analysis, outcomesModule primaryOutcomes measure: TIA differentiation from TIA mimics, secondaryOutcomes measure: TIA differentiation from Stroke, secondaryOutcomes measure: Stroke etiology, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Neurocenter of Southern Switzerland, Ospedale Civico, status: RECRUITING, city: Lugano, state: Ticino, zip: CH-6900, country: Switzerland, contacts name: Carlo Cereda, MD, role: CONTACT, phone: +41 91 811 6691, email: carlo.cereda@eoc.ch, contacts name: Carlo Cereda, role: PRINCIPAL_INVESTIGATOR, contacts name: Giovanni Bianco, role: SUB_INVESTIGATOR, contacts name: Lucio Barile, role: SUB_INVESTIGATOR, geoPoint lat: 46.01008, lon: 8.96004, hasResults: False